Aerobic Glycolysis in Schizophrenia: Developmental Rescue or Energetic Breakdown?

Why It Matters

Understanding aerobic glycolysis in schizophrenia could yield biomarkers for early detection and novel metabolic interventions that complement existing antipsychotic treatments.

Key Takeaways

• Schizophrenia shows elevated brain lactate and reduced glucose uptake
• Mitochondrial oxidative phosphorylation defects reported in postmortem brains
• Aerobic glycolysis may support neurodevelopmental plasticity in early life
• PDK inhibition emerges as potential metabolic therapy
• Antipsychotics can further disrupt cerebral glucose metabolism

Pulse Analysis

The metabolic signature of schizophrenia has moved to the forefront of neuropsychiatric research, driven by converging evidence from FDG‑PET, magnetic resonance spectroscopy, and post‑mortem analyses. Elevated lactate levels and diminished glucose utilization point to a shift away from efficient oxidative phosphorylation toward aerobic glycolysis, a phenomenon first described in cancer cells. This metabolic re‑wiring may reflect compensatory mechanisms that sustain neuronal activity when mitochondrial function falters, but it also raises concerns about chronic energy deficits that could impair synaptic signaling and myelin maintenance.

A growing body of work frames aerobic glycolysis as a developmental adaptation. During critical periods of brain growth, glycolytic flux supplies not only ATP but also biosynthetic precursors for lipid synthesis, supporting myelination and dendritic arborization. In schizophrenia, dysregulated glycolysis may initially rescue neurodevelopmental trajectories, yet persistent reliance on this pathway could become maladaptive, contributing to the white‑matter abnormalities and cognitive deficits documented in adult patients. The duality of this process—protective in youth, detrimental later—highlights the need to map glycolytic activity across disease stages.

Therapeutically, targeting the PDK‑PDH axis offers a promising avenue to rebalance brain metabolism. Inhibitors of PDK have shown synergistic effects with existing antipsychotics in preclinical models, reducing lactate accumulation and enhancing oxidative capacity. Moreover, metabolic adjuncts such as ketogenic diets or NAD⁺ precursors are under investigation for their potential to restore redox homeostasis. As precision psychiatry evolves, integrating metabolic biomarkers with genetic and neuroimaging data could enable personalized interventions that address both the neurochemical and energetic dimensions of schizophrenia.